Elevated TAGs, in correlation with the cholesterol dynamics governed by SREBP-2, and the lipotoxic potential of ceramides emerge as pivotal players in the pathogenesis of MASLD disease. This evidence concerns the gene SREBF2 and metabolic dysfunction-associated steatotic liver disease.